BioRay's ROR1-Targeting Dual-Epitope ADC Drug BR111 Receives Formal Clinical Trial Approval from NMPA ...Middle East

SHANGHAI, Feb. 10, 2025 /PRNewswire/ -- On December 19, 2024, BioRay Pharmaceutical Co., Ltd. ("BioRay") announced that the National Medical Products Administration (NMPA) has accepted the clinical trial application for its self-developed Class 1 innovative therapeutic biological product,...

Read More Details
Finally We wish PressBee provided you with enough information of ( BioRay's ROR1-Targeting Dual-Epitope ADC Drug BR111 Receives Formal Clinical Trial Approval from NMPA )

Also on site :

• Syria Launches New National Visual Identity
• Supreme Court clears way for deportation to South Sudan of several immigrants with no ties there
• Little Debbie's Surprising New Treat Leaks and Fans Want '15 of Them'